News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
259,204 Results
Type
Article (13832)
Company Profile (293)
Press Release (245079)
Section
Business (79305)
Career Advice (147)
Deals (13176)
Drug Delivery (31)
Drug Development (50264)
Employer Resources (31)
FDA (5668)
Job Trends (5110)
News (144022)
Policy (10013)
Tag
Academia (901)
Alliances (21440)
Alzheimer's disease (731)
Approvals (5632)
Artificial intelligence (61)
Bankruptcy (97)
Best Places to Work (4468)
Biotechnology (241)
Breast cancer (57)
Cancer (603)
Cardiovascular disease (52)
Career advice (128)
CAR-T (48)
Cell therapy (156)
Clinical research (39607)
Collaboration (205)
Compensation (85)
COVID-19 (998)
C-suite (58)
Cystic fibrosis (61)
Data (641)
Diabetes (65)
Diagnostics (1191)
Earnings (28677)
Events (46602)
Executive appointments (157)
FDA (5917)
Funding (210)
Gene editing (51)
Gene therapy (130)
GLP-1 (292)
Government (1063)
Healthcare (6528)
Infectious disease (1028)
Inflammatory bowel disease (89)
IPO (7169)
Job creations (859)
Job search strategy (124)
Layoffs (182)
Legal (1372)
Lung cancer (102)
Manufacturing (68)
Medical device (2547)
Medtech (2548)
Mergers & acquisitions (6090)
Metabolic disorders (204)
Neuroscience (913)
NextGen Class of 2024 (1997)
Non-profit (842)
Northern California (810)
Obesity (117)
Opinion (90)
Parkinson's disease (55)
Patents (47)
People (24902)
Pharmaceutical (48)
Phase I (13924)
Phase II (18413)
Phase III (11689)
Pipeline (168)
Postmarket research (846)
Preclinical (5885)
Radiopharmaceuticals (203)
Rare diseases (144)
Real estate (1409)
Regulatory (8166)
Research institute (930)
Southern California (749)
Startups (1963)
United States (6793)
Vaccines (154)
Weight loss (74)
Date
Today (125)
Last 7 days (535)
Last 30 days (1931)
Last 365 days (20590)
2024 (17933)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16771)
Australia (2821)
California (1839)
Canada (654)
China (137)
Colorado (70)
Connecticut (72)
Europe (36106)
Florida (198)
Georgia (53)
Illinois (113)
Indiana (53)
Kansas (54)
Maryland (278)
Massachusetts (1536)
Michigan (45)
Minnesota (83)
New Jersey (497)
New York (552)
North Carolina (384)
Northern California (810)
Ohio (73)
Pennsylvania (386)
South America (207)
Southern California (749)
Texas (192)
Washington State (199)
259,204 Results for "maplight therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Maplight Therapeutics Expands Executive Leadership Team With Appointment of Vishwas Setia as Chief Financial Officer
MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted novel therapeutics to improve the lives of patients suffering from debilitating CNS disorders, announced the appointment of Vishwas Setia as Chief Financial Officer.
March 18, 2024
·
3 min read
Drug Development
MAPLIGHT THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL FOR ML-007/PAC, UNDER DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER’S DISEASE PSYCHOSIS
MapLight Therapeutics today announced initiation of a Phase 1 clinical trial evaluating ML-007/PAC, MapLight’s extended-release fixed-dose combination formulation of the novel, investigational muscarinic agonist ML-007 and a precision-matched peripherally active anticholinergic (PAC).
March 28, 2024
·
4 min read
Biotech Bay
MapLight Therapeutics Closes $225 Million Series C Funding Round to Advance Pipeline of Central Nervous System Therapeutics
MapLight Therapeutics today announced the closing of an oversubscribed $225 million Series C financing to continue the advancement of MapLight’s transformative treatments for neuropsychiatric and neurological conditions.
October 30, 2023
·
6 min read
Drug Development
MAPLIGHT THERAPEUTICS ANNOUNCES COMPLETION OF PHASE 1 CLINICAL TRIAL FOR NOVEL M1/M4 MUSCARINIC AGONIST IN DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER’S DISEASE PSYCHOSIS
MapLight Therapeutics today announced completion of a Phase 1 clinical trial evaluating the bioavailability, safety, and tolerability of an extended release formulation of ML-007, a novel M1/M4 preferring muscarinic agonist, alone and when co-administered with a precision-matched muscarinic antagonist designed to offset peripheral effects.
January 3, 2024
·
5 min read
Business
Maplight Therapeutics Appoints Kris Hanson as General Counsel
MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted, novel therapeutics to improve the lives of people with brain disorders, announced the appointment of Kris Hanson as the company’s General Counsel.
June 20, 2023
·
2 min read
Business
Maplight Therapeutics Appoints Tim Garnett, M.D. To Board of Directors
MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted, novel therapeutics to improve the lives of people with brain disorders, announced the appointment of Tim Garnett, M.D. to its Board of Directors.
July 24, 2023
·
3 min read
Business
Maplight Therapeutics Appoints Charmaine Lykins as Chief Commercial Officer
MapLight Therapeutics announced the appointment of Charmaine Lykins, MBA, as chief commercial officer, effective April 3,2023.
April 11, 2023
·
3 min read
Drug Development
MAPLIGHT THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF SECOND PHASE 1 CLINICAL TRIAL OF THE NOVEL MUSCARINIC RECEPTOR AGONIST ML-007
MapLight Therapeutics today announced completion of a second Phase 1 clinical trial evaluating ML-007, a novel M1/M4 muscarinic receptor agonist targeting brain circuits shown to be dysfunctional in neurodegenerative and neurocognitive disorders such as schizophrenia, Alzheimer’s disease psychosis, and dyskinesias.
August 24, 2023
·
5 min read
Drug Development
MAPLIGHT THERAPEUTICS ANNOUNCES COMPLETION OF PHASE 1 CLINICAL TRIAL FOR ML-007, A NOVEL THERAPY FOR THE TREATMENT OF SCHIZOPHRENIA AND DYSKINESIAS
MapLight Therapeutics today announced it has completed its Phase 1 clinical trial evaluating ML-007, the second clinical compound developed using the MapLight platform. ML-007 is an M1/M4 muscarinic agonist that targets circuits thought to be disrupted in neurologic conditions such as schizophrenia and dyskinesia.
August 18, 2022
·
2 min read
Drug Development
MAPLIGHT THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL FOR NOVEL THERAPY TO TREAT PATIENTS WITH SCHIZOPHRENIA OR DYSKINESIAS
MapLight Therapeutics announced it has initiated a Phase 1 clinical trial evaluating ML-007, a novel therapeutic developed to target circuits understood to be dysfunctional in neurologic conditions such as schizophrenia and dyskinesias.
February 4, 2022
·
2 min read
1 of 25,921
Next